Oblique Therapeutics and Targovax enter collaboration to target mutant RAS
Göteborgsbaserade Oblique Therapeutics AB har gjort potentiellt viktiga upptäckter för antikroppsutveckling mot Covid
Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
Oblique Therapeutics will be presenting at the Inaugural RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020
Oblique Therapeutics has been recognized as one of the 15 most promising Biotech startups in Europe 2019, by StartUp City magazine
Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment
Oblique Therapeutics present tumor growth inhibition and Treglowering data for OT1096 congress ESMO
We use cookies to improve the user experience on Oblique Therapeutics. Read more about Cookies
